

STELARA®(USTEKINUMAB) PRESCRIBER	ORDER FORM		
FAX COMPLETED FORM, INSURANCE INFORMATION, CLINICAL DOCUMENTATION (LATEST NOTES & LABS) to (757) 466-1128			
NEW PATIENT OR			
CHANGE ORDER: Drug Change	Dose Change	Interval Change	
Patient Name:	Phone:		Date of Birth:
Address:			·
Allergies:			
Primary Diagnosis Description:	CLINICAL INFO	RIVIATION	ICD-10 Code:
			1CD-10 Code.
Is this the first dose?			
No – date of next dose due:			
Treatments – Tried and Failed:			
PPD (negative) – date:	Active TE	3 🛛 Unknown	1
TB Status : D Last chest X-ray – date:	🗆 Other:		
Past positive TB infection, course taken:			
STELARA [®] (Ustekinumab) PRESCRIPTION			
Stelara [®] (Ustekinumab) refill as directed x 1 year			
	•	260mg (up to 55kg) 🗆	390mg (>55kg to 85kg) 🗆 520mg (>85kg)
 Initial Dose: □ IV: Infuse over at least 1 hour once (check one): □ 260mg (up to 55kg) □ 390mg (>55kg to 85kg) □ 520mg (>85kg) □ SUBQ: Nurse to inject mg SUBQ initially and repeat 4 weeks later. 			
Maintenance Dose: Nurse to inject mg SUBQ every weeks. 			
Next Dose Due Date:			
ANCILLARY ORDERS			
Pre - Medication Orders:			
□ Acetaminophen 650mg PO 30 minutes before infusion.			
□ Diphenhydramine 25mg PO 30 minutes before infusion			
□ Methylprednisolone Succinate 125mg IV push 20 minutes before infusion.			
□ Other:			
PRN Hypersensitivity Meds:			
Epinephrine 0.3mg			
Solu-Cortef 100mg			
Solu-Medrol 125mg			
Diphenhydramine 25-50mg			
 NS 500 ML (>30kg) 			
I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.			
Prescriber Signature: Date:			
PRESCRIBER INFORMATION			
Prescriber Name:	Phone:		Fax:
Address:	1		NPI:
City, State:	Zip:		Office Contact:
CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure of failure to maintain confidential to confidential confidential to confidenti			
subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to who it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law; If the reader of this message is not the intended for the use of the person or entity to who it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law; If the reader of this message is not the intended recipient, or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of the information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.			